IntroductionOvulatory dysfunction is usually caused by an endocrine disorder, of which polycystic ovary syndrome (PCOS) is the most common cause. PCOS is usually associated with estrogen levels within the normal range and can be characterized by oligo-/anovulation resulting in decreased progesterone levels. It is suggested that decreased progesterone levels may lead to more autoimmune diseases in women with PCOS. In addition, it is often claimed that there is an association between hyperprolactinemia and PCOS. In this large well-phenotyped cohort of women with PCOS, we have studied the prevalence of thyroid dysfunction and hyperprolactinemia compared to controls, and compared this between the four PCOS phenotypes.MethodsThis retrospective cross-sectional study contains data of 1429 women with PCOS and 299 women without PCOS. Main outcome measures included thyroid stimulating hormone (TSH), Free Thyroxine (FT4), and anti-thyroid peroxidase antibodies (TPOab) levels in serum, the prevalence of thyroid diseases and hyperprolactinemia.ResultsThe prevalence of thyroid disease in PCOS women was similar to that of controls (1.9% versus 2.7%; P = 0.39 for hypothyroidism and 0.5% versus 0%; P = 0.99 for hyperthyroidism). TSH levels were also similar (1.55 mIU/L versus 1.48 mIU/L; P = 0.54). FT4 levels were slightly elevated in the PCOS group, although within the normal range (18.1 pmol/L versus 17.7 pmol/L; P < 0.05). The prevalence of positive TPOab was similar in both groups (5.7% versus 8.7%; P = 0.12). The prevalence of hyperprolactinemia was similarly not increased in women with PCOS (1.3%% versus 3%; P = 0.05). In a subanalysis of 235 women with PCOS and 235 age- and BMI-matched controls, we found no differences in thyroid dysfunction or hyperprolactinemia. In according to differences between PCOS phenotypes, only the prevalence of subclinical hypothyroidism was significantly higher in phenotype B (6.3%, n = 6) compared to the other phenotypes.ConclusionWomen with PCOS do not suffer from thyroid dysfunction more often than controls. Also, the prevalence of positive TPOab, being a marker for future risk of thyroid pathology, was similar in both groups. Furthermore, the prevalence of hyperprolactinemia was similar in women with PCOS compared to controls.

The estimated prevalence of thyroid disorder increased in Italy from 2016 to 2022. In 2016, around 14 percent of the Italian clients of general practitioners suffered from thyroid disorders. In 2021 and 2022, the prevalence of this disorder in Italy was 17.1 percent, the highest figure registered in the period under consideration. This statistic displays the prevalence of thyroid disorder in Italy from 2016 to 2022.

Thyroid Disorder Market Outlook

The global thyroid disorder market size was valued at approximately $2.5 billion in 2023 and is projected to reach around $4.7 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period. This growth is largely driven by the increasing prevalence of thyroid disorders worldwide, which necessitates the need for effective diagnostic and treatment options.

One of the primary growth factors for the thyroid disorder market is the rising incidence of thyroid diseases, such as hypothyroidism, hyperthyroidism, and thyroid cancer. According to various health organizations, the number of people suffering from thyroid disorders has been steadily increasing, which is attributed to factors such as aging populations, exposure to environmental pollutants, and genetic predispositions. This surge in the patient population is creating a robust demand for diagnostic and therapeutic solutions, thereby propelling the market forward.

Advancements in medical technology and pharmaceuticals are also significantly contributing to market growth. Innovations in diagnostic tools, such as high-resolution imaging and sensitive blood tests, are enabling earlier and more accurate detection of thyroid disorders. Additionally, the development of new medications and targeted therapies is enhancing treatment efficacy and patient outcomes. These technological advancements are making it possible to manage thyroid disorders more effectively, thus driving market expansion.

The growing awareness about thyroid health is another crucial growth factor. Public health initiatives and awareness campaigns are educating people about the importance of thyroid health, the symptoms of thyroid disorders, and the available treatment options. This increased awareness is leading to higher diagnostic rates and prompt treatment, thereby reducing disease burden and improving quality of life for patients. Moreover, the rise of telemedicine and online consultations has made it easier for patients to access medical advice and treatment, further boosting market growth.

Disorder Type Analysis

Hypothyroidism is one of the most common thyroid disorders, characterized by an underactive thyroid gland that does not produce enough thyroid hormones. The segment accounted for the largest share of the market in 2023 and is expected to maintain its dominance throughout the forecast period. The high prevalence of hypothyroidism, coupled with the availability of effective treatment options, such as synthetic thyroid hormones, is driving this segment's growth. Additionally, ongoing research into more efficient and patient-friendly treatments is likely to further boost the segment.

Hyperthyroidism Medications play a crucial role in managing the symptoms of an overactive thyroid gland. These medications, which include anti-thyroid drugs like methimazole and propylthiouracil, work by inhibiting the production of thyroid hormones, thus helping to restore hormonal balance in the body. The availability of these medications has significantly improved the quality of life for patients suffering from hyperthyroidism, allowing them to manage their condition effectively. In addition to traditional medications, ongoing research is exploring new drug formulations and delivery methods to enhance treatment efficacy and minimize side effects. This focus on innovation is expected to drive further growth in the hyperthyroidism treatment segment, offering patients more personalized and effective therapeutic options.

Hyperthyroidism, characterized by an overactive thyroid gland, is another significant segment within the thyroid disorder market. Although less common than hypothyroidism, hyperthyroidism can lead to severe health complications if left untreated. The segment is expected to grow at a steady rate due to the increasing awareness about the condition and the availability of various treatment options, such as anti-thyroid medications and radioactive iodine therapy. Newer treatment modalities and improved diagnostic techniques are also contributing to the segment's growth.

Thyroid cancer represents a smaller but rapidly growing segment within the thyroid disorder market. The incidence of thyroid cancer has been rising globally, driven by factors such as increased diagnostic scrutiny and genetic predispositions. The development of targeted therapies and advanced surgical techniques is significantly improving pa

Thyroid Disease Detection

## Overview

Thyroid Disease Detection is a dataset for object detection tasks - it contains Cancer annotations for 646 images.

## Getting Started

You can download this dataset for use within your own projects, or fork it into a workspace on Roboflow to create your own model.

  ## License

  This dataset is available under the [CC BY 4.0 license](https://creativecommons.org/licenses/CC BY 4.0).

As per the results of a large scale survey conducted across India in 2021, about ** percent of the respondents above 60 years of age suffered from thyroid problems. Whereas around **** percent of the respondents below 19 years of age reported to have thyroid issues.

Background: In adults, a significant impact of thyroid dysfunction and autoimmunity on health-related quality of life (HRQoL) and mental health is described. However, studies in children and adolescents are sparse, underpowered, and findings are ambiguous.Methods: Data from 759 German children and adolescents affected by thyroid disease [subclinical hypothyroidism: 331; subclinical hyperthyroidism: 276; overt hypothyroidism: 20; overt hyperthyroidism: 28; Hashimoto's thyroiditis (HT): 68; thyroid-peroxidase antibody (TPO)-AB positivity without apparent thyroid dysfunction: 61] and 7,293 healthy controls from a nationwide cross-sectional study (“The German Health Interview and Examination Survey for Children and Adolescents”) were available. Self-assessed HRQoL (KINDL-R) and mental health (SDQ) were compared for each subgroup with healthy controls by analysis of covariance considering questionnaire-specific confounding factors. Thyroid parameters (TSH, fT4, fT3, TPO-AB levels, thyroid volume as well as urinary iodine excretion) were correlated with KINDL-R and SDQ scores employing multiple regression, likewise accounting for confounding factors.Results: The subsample of participants affected by overt hypothyroidism evidenced impaired mental health in comparison to healthy controls, but SDQ scores were within the normal range of normative data. Moreover, in no other subgroup, HRQoL or mental health were affected by thyroid disorders. Also, there was neither a significant relationship between any single biochemical parameter of thyroid function and HRQoL or mental health, nor did the combined thyroid parameters account for a significant proportion of variance in either outcome measure. Importantly, the present study was sufficiently powered to identify even small effects in children and adolescents affected by HT, subclinical hypothyroidism, and hyperthyroidism.Conclusions: In contrast to findings in adults, and especially in HT, there was no significant impairment of HRQoL or mental health in children and adolescents from the general pediatric population affected by thyroid disease. Moreover, mechanisms proposed to explain impaired mental health in thyroid dysfunction in adults do not pertain to children and adolescents in the present study.

Thyroid Function Test Market Outlook

The global thyroid function test market was valued at approximately $1.2 billion in 2023 and is projected to reach around $2.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. The market size is primarily driven by the increasing prevalence of thyroid diseases, rising awareness about thyroid disorders, and advances in diagnostic technologies. The high incidence of conditions like hypothyroidism and hyperthyroidism among the global population is a significant growth factor for this market.

One of the major growth factors for the thyroid function test market is the rising awareness and increasing diagnostic rates of thyroid disorders. As healthcare systems around the world become more advanced and accessible, more individuals are being diagnosed with thyroid conditions at earlier stages. This has been bolstered by public health initiatives focusing on the importance of early diagnosis and management of thyroid-related diseases. Furthermore, the rise in routine health check-ups that include thyroid function tests has contributed significantly to market growth.

Technological advancements in diagnostic tools and methods are another critical driver of market expansion. Innovations such as high-sensitivity TSH assays, point-of-care testing, and the integration of artificial intelligence in diagnostic processes have revolutionized the accuracy and speed of thyroid tests. These advancements not only improve diagnostic accuracy but also enhance patient outcomes by enabling timely and effective treatment interventions. As a result, healthcare providers are increasingly adopting these advanced technologies, which, in turn, drives market growth.

The growing geriatric population and the associated rise in the prevalence of thyroid disorders among elderly individuals is also contributing to the market's growth. Older adults are more susceptible to thyroid dysfunction, necessitating regular thyroid function tests for effective management. Additionally, the increased focus on personalized medicine and the importance of tailored treatment plans have further highlighted the need for accurate thyroid function testing, thereby propelling market demand.

The Anti thyroglobulin Antibody Test Kit plays a crucial role in the diagnosis and management of autoimmune thyroid diseases. This test kit is specifically designed to detect antibodies against thyroglobulin, a protein produced by the thyroid gland. The presence of these antibodies can indicate conditions such as Hashimoto's thyroiditis or Graves' disease, which are common causes of thyroid dysfunction. By providing accurate and early detection, the Anti thyroglobulin Antibody Test Kit aids healthcare professionals in tailoring treatment plans and monitoring disease progression. The growing prevalence of autoimmune thyroid disorders has led to an increased demand for these specialized test kits, further driving market growth.

Regional outlook for the thyroid function test market indicates significant growth potential in various parts of the world. North America and Europe are expected to remain dominant due to their advanced healthcare infrastructure, high awareness levels, and robust diagnostic frameworks. However, the Asia Pacific region is anticipated to witness the fastest growth during the forecast period due to the increasing healthcare expenditure, improving diagnostic facilities, and growing awareness about thyroid disorders. Latin America and the Middle East & Africa are also expected to show moderate growth, driven by rising healthcare initiatives and improving access to diagnostic services.

Test Type Analysis

The thyroid function test market can be segmented based on test types, including TSH Test, T3 Test, T4 Test, and others. The TSH (Thyroid Stimulating Hormone) Test is the most commonly used test and holds the largest market share. This is due to its high sensitivity and reliability in detecting thyroid dysfunction. TSH tests are often the first-line diagnostic tool for evaluating thyroid function and are widely recommended by healthcare professionals. The increasing prevalence of thyroid disorders and the routine use of TSH tests in screening programs contribute significantly to their market dominance.

The "https://dataintelo.com/report/global-free-triiodothyronine-test-kit-market" target="_blank">Fr

BackgroundThyroid dysfunction significantly affects the health and development of adolescents. However, comprehensive studies on its prevalence and characteristics in US adolescents are lacking.MethodsWe investigated the prevalence of thyroid dysfunction in US adolescents aged 12–18 years using data from the National Health and Nutrition Examination Survey (NHANES) 2001–2002 and 2007–2012 cycles. Thyroid dysfunction was assessed using serum thyroid-stimulating hormone (TSH) and free thyroxine (fT4) measurements. We analyzed the prevalence across demographic subgroups and identified associated risk factors.ResultsThe study included 2,182 participants, representing an estimated 12.97 million adolescents. The group had a weighted mean age of 15.1 ± 0.06 years, with males constituting 51.4%. Subclinical hyperthyroidism emerged as the most prevalent thyroid dysfunction, affecting 4.4% of the population. From 2001–2002 to 2011–2012, subclinical hyperthyroidism remained consistent at 4.99% vs. 5.13% in the overall cohort. Subclinical and overt hypothyroidism was found in 0.41 and 1.03% of adolescents respectively, and overt hyperthyroidism was rare (0.04%). The prevalence of thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) positivity in the overall population were 5.8 and 9.8%, respectively. Positivity for TgAb was risk factors for hypothyroidism, while older age, female and Black Americans were risk factors for hyperthyroidism. Female adolescents and adolescents with an older age were more likely to be positive for TPOAb and TgAb, while Black and Mexican Americans had a lower risk of TPOAb and TgAb positivity.ConclusionSubclinical hyperthyroidism was the most common form of thyroid dysfunction, and its prevalence remained stable from 2001–2002 to 2011–2012. Notable disparities in the prevalence of hyperthyroidism and antibody positivity were observed among different age, sex and racial/ethnic groups.

BackgroundObservational studies have reported an association between coronavirus disease 2019 (COVID-19) risk and thyroid dysfunction, but without a clear causal relationship. We attempted to evaluate the association between thyroid function and COVID-19 risk using a bidirectional two-sample Mendelian randomization (MR) analysis.MethodsSummary statistics on the characteristics of thyroid dysfunction (hypothyroidism and hyperthyroidism) were obtained from the ThyroidOmics Consortium. Genome-wide association study statistics for COVID-19 susceptibility and its severity were obtained from the COVID-19 Host Genetics Initiative, and severity phenotypes included hospitalization and very severe disease in COVID-19 participants. The inverse variance-weighted (IVW) method was used as the primary analysis method, supplemented by the weighted-median (WM), MR-Egger, and MR-PRESSO methods. Results were adjusted for Bonferroni correction thresholds.ResultsThe forward MR estimates show no effect of thyroid dysfunction on COVID-19 susceptibility and severity. The reverse MR found that COVID-19 susceptibility was the suggestive risk factor for hypothyroidism (IVW: OR = 1.577, 95% CI = 1.065–2.333, P = 0.022; WM: OR = 1.527, 95% CI = 1.042–2.240, P = 0.029), and there was lightly association between COVID-19 hospitalized and hypothyroidism (IVW: OR = 1.151, 95% CI = 1.004–1.319, P = 0.042; WM: OR = 1.197, 95% CI = 1.023-1.401, P = 0.023). There was no evidence supporting the association between any phenotype of COVID-19 and hyperthyroidism.ConclusionOur results identified that COVID-19 might be the potential risk factor for hypothyroidism. Therefore, patients infected with SARS-CoV-2 should strengthen the monitoring of thyroid function.

As per the results of a large scale survey conducted across India in 2021, about *** percent of the respondents suffered from thyroid related problems. This was a slight fall in the share of people with thyroid issues when compared to the previous year of the survey.

The Thyroid Gland Disorders Treatment Market report segments the industry into By Type Of Disorder (Hypothyroidism, Hyperthyroidism, Other Types Of Disorder), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By Drug Class (Thioamides, Ionic Inhibitors, Hormone-release Inhibitors, Other Drug Classes), By Distribution Channel (Wholesale Distribution, Retail Stores, and more), and Geography.

Background: Sex and age have substantial influence on thyroid function. Sex influences the risk and clinical expression of thyroid disorders (TDs), with age a proposed trigger for the development of TDs. Cardiac function is affected by thyroid hormone levels with gender differences. Accordingly, we investigated the proteomic changes involved in sex based cardiac responses to thyroid dysfunction in elderly mice. Methods: Aged (18-20 months) male and female C57BL/6 mice were fed diets to create euthyroid, hypothyroid, or hyperthyroid states. Serial echocardiographs were performed to assess heart function. Proteomic changes in cardiac protein profiles were assessed by 2-D DIGE and LC-MS/MS, and a subset confirmed by immunoblotting. Results: Serial echocardiographs showed ventricular function remained unchanged regardless of treatment. Heart rate and size increased (hyperthyroid) or decreased (hypothyroid) independent of sex. Pairwise comparison between the six groups identified 55 proteins (≥ 1.5-fold difference and p < 0.1). Compared to same-sex controls 26/55 protein changes were in the female hypothyroid heart, whereas 15/55 protein changes were identified in the male hypothyroid, and male and female hyperthyroid heart. The proteins mapped to oxidative phosphorylation, tissue remodeling and inflammatory response pathways. Conclusion: We identified both predicted and novel proteins with gender specific differential expression in response to thyroid hormone status, providing a catalogue of proteins associated with thyroid dysfunction. Pursuit of these proteins and their involvement in cardiac function will expand our understanding of mechanisms involved in sex-based cardiac response to thyroid dysfunction.

The global market for Thyroid Gland Disorders Treatment is experiencing robust growth, driven by increasing prevalence of thyroid disorders, particularly hypothyroidism and hyperthyroidism, across various demographics and geographic regions. The rising geriatric population, a known risk factor for thyroid dysfunction, is significantly contributing to market expansion. Technological advancements in diagnostic tools, leading to earlier and more accurate diagnoses, coupled with the development of innovative and more targeted therapies, are further fueling market growth. While the exact market size in 2025 is unavailable, based on industry reports and average growth rates for similar pharmaceutical markets, a reasonable estimate could be in the range of $20-25 billion. Assuming a CAGR (Compound Annual Growth Rate) of, for instance, 5% (a conservative estimate given the factors mentioned), the market is projected to reach a substantial value by 2033. Market segmentation reveals a significant portion of the demand originating from hospital and clinic settings for both hypothyroidism and hyperthyroidism treatments. However, the "other" application segment, potentially including home-based treatments and self-management support, is also expected to grow, driven by telehealth advancements and patient preference for convenient care. Leading pharmaceutical companies like AbbVie, Merck KGaA, and Pfizer are key players, constantly innovating and investing in research and development to enhance treatment options and broaden their market share. Regional analysis would indicate significant market presence in North America and Europe, with emerging markets in Asia Pacific showing promising growth potential due to increasing healthcare expenditure and improved healthcare infrastructure. Challenges include the need for increased awareness and early detection in certain regions, alongside potential pricing pressures and the complexities of managing long-term conditions.

In subclinical hypothyroidism, the presence of depressive symptoms is often a reason for starting levothyroxine treatment. However, data are conflicting on the association between subclinical thyroid dysfunction and depressive symptoms. We aimed to examine the association between subclinical thyroid dysfunction and depressive symptoms in all prospective cohorts with relevant data available. We performed a systematic review of the literature from Medline, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Library from inception to 10th May 2019. We included prospective cohorts with data on thyroid status at baseline and depressive symptoms during follow-up. The primary outcome was depressive symptoms measured at first available follow-up, expressed on the Beck’s Depression Inventory (BDI) scale (range 0–63, higher values indicate more depressive symptoms, minimal clinically important difference: 5 points). We performed a two-stage individual participant data (IPD) analysis comparing participants with subclinical hypo- or hyperthyroidism versus euthyroidism, adjusting for depressive symptoms at baseline, age, sex, education, and income (PROSPERO CRD42018091627). Six cohorts met the inclusion criteria, with IPD on 23,038 participants. Their mean age was 60 years, 65% were female, 21,025 were euthyroid, 1342 had subclinical hypothyroidism and 671 subclinical hyperthyroidism. At first available follow-up [mean 8.2 (± 4.3) years], BDI scores did not differ between participants with subclinical hypothyroidism (mean difference = 0.29, 95% confidence interval = − 0.17 to 0.76, I2 = 15.6) or subclinical hyperthyroidism (− 0.10, 95% confidence interval = − 0.67 to 0.48, I2 = 3.2) compared to euthyroidism. This systematic review and IPD analysis of six prospective cohort studies found no clinically relevant association between subclinical thyroid dysfunction at baseline and depressive symptoms during follow-up. The results were robust in all sensitivity and subgroup analyses. Our results are in contrast with the traditional notion that subclinical thyroid dysfunction, and subclinical hypothyroidism in particular, is associated with depressive symptoms. Consequently, our results do not support the practice of prescribing levothyroxine in patients with subclinical hypothyroidism to reduce the risk of developing depressive symptoms.

Context

The datasets featured below were created by reconciling thyroid disease datasets provided by the UCI Machine Learning Repository.

Content

The size for the file featured within this Kaggle dataset is shown below — along with a list of attributes, and their description summaries: - thyroidDF.csv - 9172 observations x 31 attributes

1. age - age of the patient (int)
2. sex - sex patient identifies (str)
3. on_thyroxine - whether patient is on thyroxine (bool)
4. query on thyroxine - *whether patient is on thyroxine (bool)
5. on antithyroid meds - whether patient is on antithyroid meds (bool)
6. sick - whether patient is sick (bool)
7. pregnant - whether patient is pregnant (bool)
8. thyroid_surgery - whether patient has undergone thyroid surgery (bool)
9. I131_treatment - whether patient is undergoing I131 treatment (bool)
10. query_hypothyroid - whether patient believes they have hypothyroid (bool)
11. query_hyperthyroid - whether patient believes they have hyperthyroid (bool)
12. lithium - whether patient * lithium (bool)
13. goitre - whether patient has goitre (bool)
14. tumor - whether patient has tumor (bool)
15. hypopituitary - whether patient * hyperpituitary gland (float)
16. psych - whether patient * psych (bool)
17. TSH_measured - whether TSH was measured in the blood (bool)
18. TSH - TSH level in blood from lab work (float)
19. T3_measured - whether T3 was measured in the blood (bool)
20. T3 - T3 level in blood from lab work (float)
21. TT4_measured - whether TT4 was measured in the blood (bool)
22. TT4 - TT4 level in blood from lab work (float)
23. T4U_measured - whether T4U was measured in the blood (bool)
24. T4U - T4U level in blood from lab work (float)
25. FTI_measured - whether FTI was measured in the blood (bool)
26. FTI - FTI level in blood from lab work (float)
27. TBG_measured - whether TBG was measured in the blood (bool)
28. TBG - TBG level in blood from lab work (float)
29. referral_source - (str)
30. target - hyperthyroidism medical diagnosis (str)
31. patient_id - unique id of the patient (str)

Target Metadata

  The diagnosis consists of a string of letters indicating diagnosed conditions.
  A diagnosis "-" indicates no condition requiring comment. A diagnosis of the
  form "X|Y" is interpreted as "consistent with X, but more likely Y". The
  conditions are divided into groups where each group corresponds to a class of
  comments.

  Letter Diagnosis
  ------ ---------

  hyperthyroid conditions:

  A  hyperthyroid
  B  T3 toxic
  C  toxic goitre
  D  secondary toxic

  hypothyroid conditions:

  E  hypothyroid
  F  primary hypothyroid
  G  compensated hypothyroid
  H  secondary hypothyroid

  binding protein:

  I  increased binding protein
  J  decreased binding protein

  general health:

  K  concurrent non-thyroidal illness

  replacement therapy:

  L  consistent with replacement therapy
  M  underreplaced
  N  overreplaced

  antithyroid treatment:

  O  antithyroid drugs
  P  I131 treatment
  Q  surgery

  miscellaneous:

  R  discordant assay results
  S  elevated TBG
  T  elevated thyroid hormones

Source

Thyroid Data - https://archive.ics.uci.edu/ml/datasets/thyroid+disease

This dataset is a cleaned, transformed, and research-informed version of the original Thyroid Disease records compiled by the Garavan Institute and J. Ross Quinlan (1984–1987). It contains 9,000+ patient records with lab values, clinical history, and diagnosis outcomes. All missing values (?) were removed, and redundant or conflicting entries were dropped.

The dataset is valuable for Healthcare and Medical Research focused on thyroid-related Health Conditions. It supports Multiclass Classification problems in Artificial Intelligence and Data Analytics, particularly within Computer Science and Healthcare domains.

Missing values have been removed and categorical flags (t/f) converted to boolean (True/False). Meaningful multiclass target labels were created based on clinical diagnosis codes, including handling ambiguous cases. Data types were adjusted for compatibility with machine learning workflows using tools like pandas, NumPy, and scikit-learn.

This dataset is suitable for users of all skill levels—Beginner, Intermediate, and Advanced—interested in exploring Classification, Feature Extraction, Data Cleaning, and Exploratory Data Analysis in healthcare datasets. Visualizations can be developed using Matplotlib and Seaborn to better understand thyroid disease patterns.

Boolean fields (t/f) were converted to True/False, and a meaningful target variable was created based on clinically grounded groupings described in the research article “Thyroid Disease Prediction Using Selective Features and Machine Learning Techniques” (PMCID: PMC9405591).

The original diagnosis strings (e.g., A|B) were resolved to reflect the most likely class, and diagnoses were mapped into simplified, interpretable categories suitable for classification tasks (e.g., hypothyroid, hyperthyroid, normal, etc.).

This version is optimized for machine learning applications such as:

• Classification of thyroid status (e.g., binary or multi-class)

• Feature selection and model evaluation

• Clinical decision support research

• Ideal for healthcare ML projects, educational purposes, and benchmarking thyroid disorder prediction models.

According to Cognitive Market Research, the global Thyroid Functioning Tests market size will be USD 4968.5 million in 2025. It will expand at a compound annual growth rate (CAGR) of 7.00% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 1838.35 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1440.8 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 1192.4 million in 2025 and will grow at a compound annual growth rate (CAGR) of 9.6% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 188.80 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2033.
Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 198.74 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.5% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 109.31 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2033.
Power Filters category is the fastest growing segment of the Thyroid Functioning Tests industry

Market Dynamics of Thyroid Functioning Tests Market

Key Drivers for Thyroid Functioning Tests Market

Rising Prevalence of Thyroid Disorders to Boost Market Growth

Hypothyroidism and hyperthyroidism are becoming increasingly prevalent worldwide due to factors such as genetics, lifestyle changes, and environmental influences. Over 12 percent of the U.S. population will develop a thyroid condition at some point in their lives, and an estimated 20 million Americans currently have some form of thyroid disease. However, up to 60 percent of those with thyroid conditions are unaware of their diagnosis. Women are more likely to experience thyroid issues, with the risk being five to eight times higher than that of men. In fact, one in eight women will develop a thyroid disorder during their lifetime. These conditions can have a significant impact on metabolism and overall health, contributing to a growing demand for thyroid function tests. Additionally, autoimmune diseases, such as Hashimoto's thyroiditis (a common cause of hypothyroidism) and Graves' disease (which causes hyperthyroidism), are becoming more prevalent, further increasing the need for regular screening. As the global population ages, the likelihood of developing thyroid disorders, particularly hypothyroidism, also rises. This aging demographic requires more routine testing to monitor and manage thyroid health.

https://www.thyroid.org/media-main/press-room//./

Rise in Lifestyle-related Risk Factors to Boost Market Growth

Increasing stress, poor diet, lack of physical activity, and environmental pollution are major risk factors for thyroid disorders. Approximately 284 million people worldwide suffer from anxiety disorders, and nearly 90% of U.S. adults report losing sleep due to concerns about health and the economy. Additionally, about 75% of Americans experience physical or mental symptoms of stress, with more than three-quarters of adults reporting issues such as headaches, fatigue, and depression. These lifestyle changes are contributing to a higher incidence of thyroid-related problems, which is driving the growing demand for thyroid function tests. Furthermore, exposure to chemicals and toxins in the environment, including those found in certain pesticides, has been linked to thyroid dysfunction, further increasing the need for regular monitoring.

https://www.singlecare.com/blog/news/stress-statistics/./

Restraint Factor for the Thyroid Functioning Tests Market

High Cost of Advanced Diagnostic Tests and Challenges in Test Accuracy and Standardization, Will Limit Market Growth

The cost of diagnostic equipment for thyroid function tests, such as automated analyzers and high-quality reagents, can be prohibitively expensive, especially for small clinics and healthcare facilities in emerging markets. Additionally, testing at high-end laboratories or through advanced diagnostic platforms often comes with higher costs, which may discourage patients from undergoing regular testing. Th...

Thyroid Home Test Kits Market Outlook

The global thyroid home test kits market size was valued at USD 3.5 billion in 2023 and is projected to reach USD 6.9 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.5% during the forecast period. This growth is driven by a combination of increasing healthcare awareness, technological advancements, and the rising prevalence of thyroid disorders globally.

One of the primary growth factors propelling the thyroid home test kits market is the increased awareness about thyroid health and its impact on overall well-being. Thyroid disorders, including hypothyroidism and hyperthyroidism, can lead to severe health complications if left undiagnosed and untreated. The growing awareness among the population regarding these issues has led to a higher demand for convenient and accessible testing solutions. Thyroid home test kits provide an easy and efficient way for individuals to monitor their thyroid health without frequent visits to a healthcare facility, thus contributing to market growth.

Technological advancements in diagnostic tools and home testing kits have significantly influenced the market dynamics. The development of more accurate, reliable, and user-friendly test kits has made it easier for consumers to conduct tests at home. Innovations such as digital test kits, which provide instant results and are connected to mobile applications for continuous monitoring, have further boosted the market. These advancements not only increase the efficiency of home testing but also enhance user confidence in home-based diagnostic solutions.

The rising prevalence of thyroid disorders worldwide is another crucial factor driving the market. Various factors such as genetics, lifestyle changes, and environmental influences have contributed to an increase in thyroid-related diseases. According to the American Thyroid Association, an estimated 20 million Americans have some form of thyroid disease, with similar statistics reported globally. This high prevalence underscores the need for regular monitoring, thereby driving the demand for home test kits. Additionally, the growing geriatric population, which is more susceptible to thyroid disorders, further fuels the market growth.

From a regional perspective, North America currently holds the largest share of the thyroid home test kits market, primarily due to advanced healthcare infrastructure, high awareness levels, and a significant number of patients with thyroid disorders. Europe follows closely, with a growing emphasis on preventive healthcare and an increasing adoption of home test kits. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by improving healthcare facilities, rising awareness, and a large patient pool. Emerging economies in Latin America and the Middle East & Africa are also expected to contribute significantly to the market growth as healthcare awareness and infrastructure continue to improve.

Product Type Analysis

The product type segment of the thyroid home test kits market is categorized into TSH Test Kits, T3 Test Kits, T4 Test Kits, and Combined Test Kits. Each of these test kits serves a specific purpose in diagnosing different aspects of thyroid function. TSH Test Kits are designed to measure the levels of thyroid-stimulating hormone (TSH) in the blood, which is a primary indicator of thyroid activity. These kits are the most widely used and preferred by both healthcare professionals and consumers due to their effectiveness in diagnosing hypothyroidism and hyperthyroidism. The high prevalence of thyroid disorders and the convenience of these kits make them a significant contributor to the market.

T3 Test Kits, on the other hand, measure the levels of triiodothyronine (T3) hormone in the blood. T3 is a critical thyroid hormone that influences various bodily functions, including metabolism and energy production. These kits are particularly useful in identifying cases where TSH levels are normal, but the patient still exhibits symptoms of thyroid dysfunction. The demand for T3 Test Kits is driven by their ability to provide a more comprehensive analysis of thyroid function, making them an essential tool for accurate diagnosis.

T4 Test Kits are used to measure thyroxine (T4) hormone levels in the bloodstream. T4 is another vital hormone produced by the thyroid gland and plays a crucial role in regulating metabolism. These kits are especially important for monitoring patients with known thyroid disorders and for assessing the effectiveness of thyroid hormo

Thyroid diseases are common, and use of levothyroxine is increasing worldwide. We investigated the influence of gender, race and socioeconomic status on the diagnosis and treatment of thyroid disorders using data from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), a multicenter cohort study of civil servants (35-74 years of age) from six Brazilian cities. Diagnosis of thyroid dysfunction was by thyrotropin (TSH), and free thyroxine (FT4) if TSH was altered, and the use of specific medications. Multivariate logistic regression models were constructed using overt hyperthyroidism/hypothyroidism and levothyroxine use as dependent variables and sociodemographic characteristics as independent variables. The frequencies of overt hyper- and hypothyroidism were 0.7 and 7.4%, respectively. Using whites as the reference ethnicity, brown, and black race were protective for overt hypothyroidism (OR=0.76, 95%CI=0.64-0.89, and OR=0.53, 95%CI=0.43-0.67, respectively, and black race was associated with overt hyperthyroidism (OR=1.82, 95%CI=1.06-3.11). Frequency of hypothyroidism treatment was higher in women, browns, highly educated participants and those with high net family incomes. After multivariate adjustment, levothyroxine use was associated with female gender (OR=6.06, 95%CI=3.19-11.49) and high net family income (OR=3.23, 95%CI=1.02-10.23). Frequency of hyperthyroidism treatment was higher in older than in younger individuals. Sociodemographic factors strongly influenced the diagnosis and treatment of thyroid disorders, including the use of levothyroxine.